Navigation Links
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Date:9/21/2007

- Phase III trials now underway to evaluate vandetanib as second-line NSCLC

treatment in combination with docetaxel -

WILMINGTON, Del., Sept. 20 /PRNewswire/ -- Results published today in the Journal of Clinical Oncology(1) show that the AstraZeneca investigational once-daily oral anti-cancer drug vandetanib (ZACTIMA), in combination with docetaxel, improved progression free survival (PFS) in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

The Phase II trial - Study 6 - compared the combination of vandetanib 100mg or 300mg plus docetaxel to standard docetaxel alone. The trial demonstrated that adding vandetanib to standard docetaxel therapy prolonged median PFS to 18.7 weeks and 17 weeks respectively, compared to 12 weeks with docetaxel alone.(2)

"Given the poor prognosis in advanced non-small cell lung cancer, an increase in time to disease progression can be meaningful to patients," said Study 6 lead author John Heymach, Assistant Professor of Thoracic Head/Neck Medical Oncology at the University of Texas MD Anderson Cancer Centre . "The results of Study 6 provide encouraging support, and reinforce further investigation with ZACTIMA in combination with chemotherapy in Phase III trials."

Based on these data, AstraZeneca has initiated a Phase III trial, currently underway, to evaluate vandetanib and docetaxel in second-line treatment of non-small cell lung cancer. The ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer), trial is a randomised, double- blind study evaluating vandetanib 100mg in combination with docetaxel vs. docetaxel alone, in patients with locally advanced or metastatic NSCLC after failure of first-line treatment.

The study is recruiting and aims to enroll approximately 1400 patients worldwide at over 250 centers throughout Europe, North America, South America and Asia Pacific. The primary end points of the study are to assess PFS. Response rates and overall Sur
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... July 30, 2015  Cleveland Clinic President Wael ... address last month that industry is compelled to adopt ... gain the efficiencies—and develop the transformational innovations -- required ... comments were preceded by Doug Kohrs , past ... moderator, who stressed that industry must add "episode of ...
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... N.Y., June 23 A landmark study has ... failure or death in patients with heart disease ... with defibrillator (CRT-D) versus patients who received only ... , MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), a ... the development of prescription drugs that target unmet medical,needs, ... Moapar(R),and Salvapar(R)), was launched in Germany in May 2009, ... also launched on a preliminary basis in,Belgium. The effective ...
Cached Medicine Technology:New Therapy Found to Prevent Heart Failure 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
(Date:7/30/2015)... , ... July 30, 2015 , ... In a meaningful ... at Serenity Palms Drug Addiction Treatment Center have created an addiction graveyard. Sharing this ... of its most beloved residents, Rocky Hudson . Hudson (1945-2015) fell in love ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine ... Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected ... vendors, will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual ...
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... , ... July 30, 2015 ... ... a video, “Beachside Nursing Center,” to announce its position as one of ... Beachside's administrator and staff members support the CMS rating system, which monitors ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... company and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to ... new collaboration, OncLive’s editorial and marketing groups will help spread the news about ...
Breaking Medicine News(10 mins):Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:Beachside Nursing Center Releases New Video 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... account , TUESDAY, Sept. 1 (HealthDay News) -- Many hospitals ... Report list of best hospitals for heart disease but ... say. , "If you really want to know how a ... readmission, you should look directly at government statistics for those ...
... flu strains , TUESDAY, Sept. 1 (HealthDay News) -- Fears ... this year may be unfounded, say researchers at the University ... the swine flu pandemic did not take a virulent turn ... did spread more rapidly than the other viruses, confirming the ...
... , PISCATAWAY, N.J., Sept. 1 ... in advanced injection technologies, today announced that Leslie Bernhard, an ... Leonard Osser who had previously led the Company as Chairman ... interim Chief Executive Officer since February 2009 and was formerly ...
... Ind., Sept. 1 Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ... the month of September: , , , ... 2009, at 11:30 a.m. Eastern Time; , Morgan Stanley ... 8:35 a.m. Eastern Time; and , UBS Global Life ...
... , CARDIFF, Calif., Sept. 1 ... http://www.jedimindinc.com ) announced today that their Medical Division ... patients in wheelchairs. An estimated 1.6 million Americans residing outside ... Health Interview Survey on Disability (NHIS-D). Jedi Mind,s Medical Division ...
... ... Drug Development, Regulatory Approval, and Access to Patients from October 15-16, 2009 in Toronto, ... ... will host Personalized Medicine: Biomarkers and Diagnostics in Drug Development, Regulatory Approval, and ...
Cached Medicine News:Health News:Government Best Source for U.S. Hospital Data, Study Finds 2Health News:Swine Flu May Be Less Dangerous Than Predicted: Study 2Health News:Swine Flu May Be Less Dangerous Than Predicted: Study 3Health News:Milestone Scientific Announces Key Leadership Changes 2Health News:Milestone Scientific Announces Key Leadership Changes 3Health News:Jedi Mind Medical Applications Division to Concentrate on Wheelchair Mobility Applications 2Health News:DIA Conference to Explore The Science and Scope of Personalized Medicine 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: